

Inhalation And Nasal Spray Generic Drugs Market Size, Share & Trends Analysis Report By Product

*The Business Research Company's
Inhalation And Nasal Spray Generic
Drugs Global Market Report 2025 –
Market Size, Trends, And Global Forecast
2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, November 25, 2025

/EINPresswire.com/ -- What Is The

[Inhalation And Nasal Spray Generic Drugs Market Size And Growth?](#)

The market size for generic inhalation and nasal spray drugs has seen substantial growth in the past few years. The forecast suggests a rise from \$29.71 billion in 2024 to \$31.53 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.1%. This historic growth is often



"Get 20% Off All Global
Market Reports With Code
ONLINE20 – Stay Ahead Of
Trade Shifts,
Macroeconomic Trends, And
Industry Disruptors"

*The Business Research
Company*

associated with the growth in respiratory diseases, the affordability of alternatives, government-led pushes for generics, the entrance of generic manufacturers into the market, policies encouraging a switch to generics, and regulatory backing for generics.

The generic drugs market for inhalation and nasal spray is predicted to witness robust growth in the forthcoming years. The market is anticipated to reach \$42.53 billion by 2029, experiencing a compound annual growth rate (CAGR) of 7.8%. Factors such as an increasingly aging population,

wider generic pipeline, initiatives by pharmacies and retailers, a significant global burden of respiratory diseases, competition from biosimilars, and patient preference for generic options all contribute to the growth predicted for this period. The forecast period will also see major trends such as advancements in inhalation drug deliveries, focus on biosimilar nasal sprays, industry collaborations and partnerships, the patient-oriented design of inhalers, and a move towards over-the-counter nasal sprays.

Download a free sample of the inhalation and nasal spray generic drugs market report:

The Business
Research Company

The Business Research Company



What Are The Current Leading [Growth Drivers For Inhalation And Nasal Spray Generic Drugs Market](#)?

The global increase in chronic respiratory illnesses is anticipated to drive the expansion of the inhalation and nasal spray generic drug industry. These chronic respiratory disorders impact the airways and other parts of the lungs. For instance, data from the Australian Institute of Health and Welfare, a national agency based in Australia, revealed in June 2023 that nearly a third (30%), i.e., 7.5 million Australians, have been diagnosed with chronic respiratory illnesses. Thus, the upward trend of such diseases worldwide is anticipated to facilitate market growth.

Which Companies Are Currently Leading In The Inhalation And Nasal Spray Generic Drugs Market?

Major players in the Inhalation And Nasal Spray Generic Drugs include:

- Teva Pharmaceuticals Inc.
- Sandoz International GmbH
- Akorn Operating Company LLC
- Cipla Inc.
- Apotex Inc.
- Impax Laboratories LLC
- Bausch Health Companies Inc.
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Sun Pharmaceutical Industries Ltd.

What Are The Main Trends, Positively Impacting The [Growth Of Inhalation And Nasal Spray Generic Drugs Market](#)?

Key trends in the market are characterized by strategic alliances and co-operations. Primary competitors in the inhalation and nasal spray generic drugs industry are strengthening their standing through these partnerships and collaborations. An example of this trend can be seen in Glenmark Pharmaceuticals Limited's February 2022 collaboration with biotech organization, SaNOtize. Glenmark, a globally recognized, research-based pharmaceutical company from India, partnered with the Canadian firm for the purpose of launching the Nitric Oxide Nasal Spray (NONS) to treat adult COVID-19 patients in India.

How Is The Inhalation And Nasal Spray Generic Drugs Market Segmented?

The inhalation and nasal spray generic drugs market covered in this report is segmented –

- 1) By Drug Class: Corticosteroids, Bronchodilators, Antihistamines, Combinations, Decongestant Sprays
- 2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Other Indications
- 3) By Patient Demographics: Geriatric Patient, Adult Patient, Pediatric Patient

4) By End-User: Hospitals, Homecare, Other End-Users

Subsegments:

- 1) By Corticosteroids: Fluticasone, Budesonide, Beclomethasone, Mometasone
- 2) By Bronchodilators: Short-Acting Beta Agonists (SABAs), Long-Acting Beta Agonists (LABAs), Anticholinergics
- 3) By Antihistamines: Azelastine, Olopatadine, Levocabastine
- 4) By Combinations: Corticosteroid And Long-Acting Beta Agonist (LABA) Combinations, Antihistamine And Decongestant Combinations
- 5) By Decongestant Sprays: Oxymetazoline, Phenylephrine, Xylometazoline

View the full inhalation and nasal spray generic drugs market report:

<https://www.thebusinessresearchcompany.com/report/inhalation-and-nasal-spray-generic-drugs-global-market-report>

Which Is The Dominating Region For The Inhalation And Nasal Spray Generic Drugs Market? In 2024, North America dominated the inhalation and nasal spray generic drugs market and is anticipated to continue its rapid growth in the future. The report covering this market includes regions such as Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the Global Inhalation And Nasal Spray Generic Drugs Market 2025, By The Business Research Company

Drug Delivery Devices Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report>

Drugs For Immunotherapy Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report>

Drugs For Hormonal Replacement Therapy Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/869762185>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.